Floatz logo

Synkir-310

Aggressive B-Cell Non-Hodgkin Lymphoma

Verismo TherapeuticsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Aggressive B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 3BB
LIPEGFILGRASTIM
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3BB
Eloxatin
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 2BB
(+)-VINCRISTINE
Universität des Saarlandes
Phase 3B
PEGFILGRASTIM
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3B

View all 50 →

Same molecule, other indications

Synkir-310 is also rated in:

non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
indolent B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangementDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →